Geneos Therapeutics, Inc. (Details) - Geneos Therapeutics, Inc. - USD ($) $ in Thousands |
Jun. 30, 2025 |
Dec. 31, 2024 |
|---|---|---|
| Noncontrolling Interest [Line Items] | ||
| Noncontrolling interest, ownership percentage by parent (in percent) | 23.00% | |
| Investment in Geneos | $ 0 | $ 0 |
| Equity method investments, minimum | $ 0 |
| X | ||||||||||
- Definition Equity Method Investments, Minimum No definition available.
|
| X | ||||||||||
- Definition This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition The parent entity's interest in net assets of the subsidiary, expressed as a percentage. No definition available.
|
| X | ||||||||||
- Details
|